Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195757 | 0.88 | TLR7 (0.46) | CSF1RNTRK2TLR7TLR8CYP2D6 | |
| SCHEMBL17035555 | 0.88 | FLT3 (0.43) | CSF1RNTRK2TLR7TLR8CYP2D6 | |
| SCHEMBL17035548 | 0.86 | TLR7 (0.64) | TLR7TLR8CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL23472185 | 0.86 | TLR7 (0.59) | TLR7TLR8CYP2D6CYP2C9 | |
| SCHEMBL20219412 | 0.84 | TLR7 (0.46) | TLR7TLR8CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL23472375 | 0.82 | L3MBTL1 (0.46) | TLR7TLR8L3MBTL1 | |
| SCHEMBL23472150 | 0.81 | DHFR (0.51) | TLR7TLR8CYP1A2L3MBTL1 | |
| SCHEMBL20219619 | 0.81 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL20219638 | 0.80 | TLR7 (0.41) | TLR7TLR8CYP1A2 | |
| SCHEMBL15470061 | 0.80 | TLR7 (0.48) | TLR7TLR8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284304-B2 | Substituted pyrimidines as toll-like receptor modulators | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-15 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, PNP | CSF1R 3967/4885NTRK2 4565/4885TLR7 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.